Summarized by Masters of Longevity from PR Newswire.
They will combine trial and real-world data with AI analytics.

Key Takeaways
- The partnership is combining Novo trial data with nference AI.
- Research is studying treatment effectiveness, safety, and progression.
- A venture framework was created to support AI-native cardiometabolic firms.



